You are here

TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CA130053
Agency Tracking Number: N43CA130053
Amount: $199,565.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BASE PAIR BIOTECHNOLOGIES, INC. 8058 EL RIO ST
HOUSTON, TX 77054-4185
United States
DUNS: 78474555
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARK MORRIS
 (713) 202-5425
 MARK@BASEPAIRBIO.COM
Business Contact
 MARK MORRIS
Phone: (713) 202-5425
Email: MARK@BASEPAIRBIO.COM
Research Institution
 Stub
Abstract

The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of proof-of-concept technologies that reliably generate anti-peptide capture reagents that can immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public sector to identify minimum characterization criteria for validation of the assays; 4) Generate affinity reagentsto at least ten proteotypic peptides and demonstrate high affinity, specificity and immunoprecipitation performance; 5) Make available to NCI sufficient reagents to perform 10 test runs for each of the ten peptides for independent evaluation; 6) Presentfindings to an NCI CPTC Evaluation Panel demonstrating how the capture reagents have improved cost effectiveness and throughput capabilities in production. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government